Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management

Overview

Journal Curr Treat Options Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2017 May 4

PMID 28466120

Citations 7

Authors

Fatima A Ballout

Ahmad S Manshad

Tochukwu M Okwuosa

Affiliations

Soon will be listed here.

Abstract

Pulmonary hypertension is caused by cancer and its therapeutic agents including chemotherapy, radiotherapy, and even the targeted therapies. Ironically, some of the cancer therapies that cause one type of pulmonary hypertension (PH) could potentially be employed in the treatment of another PH type. Greater awareness on the role of cancer therapeutic agents in causing PH is required. Conversely, since PH is mostly incurable, the potential role of some of these cancer therapeutic agents in the cure of PH should be recognized. In short, the relationship between cancer, cancer therapy, and PH is an interesting one requiring further attention, education, and research.

Citing Articles

Diagnostic enigma of pulmonary hypertension: Tale from a series of three patients.

Singhi A, Banerji A, Biswas N, Das S Med J Armed Forces India. 2024; 80(Suppl 1):S320-S324.

PMID: 39734844 PMC: 11670594. DOI: 10.1016/j.mjafi.2023.08.003.

Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications.

Leiva O, Beaty W, Soo S, Agarwal M, Yang E Rev Cardiovasc Med. 2024; 25(3):87.

PMID: 39076943 PMC: 11263834. DOI: 10.31083/j.rcm2503087.

Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice.

Gurdogan M, Demir M, Yalta K, Gulertop Y Anatol J Cardiol. 2023; 27(6):299-307.

PMID: 37257013 PMC: 10250770. DOI: 10.14744/AnatolJCardiol.2023.3013.

Pulmonary hypertension is associated with an increased incidence of cancer diagnoses.

Roderburg C, Loosen S, Hippe H, Luedde T, Kostev K, Luedde M Pulm Circ. 2022; 12(2):e12000.

PMID: 35783034 PMC: 9235867. DOI: 10.1002/pul2.12000.

A case of severe cancer-related pulmonary hypertension; An unexpected resolution.

Albaba I, Medarov B Respir Med Case Rep. 2022; 38:101671.

PMID: 35663111 PMC: 9157252. DOI: 10.1016/j.rmcr.2022.101671.

References

Hoeper M, Mayer E, Simonneau G, Rubin L . Chronic thromboembolic pulmonary hypertension. Circulation. 2006; 113(16):2011-20. DOI: 10.1161/CIRCULATIONAHA.105.602565. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016; 69(2):177. DOI: 10.1016/j.rec.2016.01.002. View

Ranchoux B, Gunther S, Quarck R, Chaumais M, Dorfmuller P, Antigny F . Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2014; 185(2):356-71. DOI: 10.1016/j.ajpath.2014.10.021. View

Snyder L, Harmon K, Estensen R . Intravascular lymphomatosis (malignant angioendotheliomatosis) presenting as pulmonary hypertension. Chest. 1989; 96(5):1199-200. DOI: 10.1378/chest.96.5.1199. View

Viskochil D, Buchberg A, Xu G, Cawthon R, Stevens J, Wolff R . Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 1990; 62(1):187-92. DOI: 10.1016/0092-8674(90)90252-a. View

Wild A, Kalff-Suske M, Vortkamp A, Bornholdt D, Konig R, Grzeschik K . Point mutations in human GLI3 cause Greig syndrome. Hum Mol Genet. 1997; 6(11):1979-84. DOI: 10.1093/hmg/6.11.1979. View

Giles F, Mauro M, Hong F, Ortmann C, McNeill C, Woodman R . Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013; 27(6):1310-5. DOI: 10.1038/leu.2013.69. View

Stewart D, Cogan J, Kramer M, Miller Jr W, Christiansen L, Pauciulo M . Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?. Chest. 2007; 132(3):798-808. DOI: 10.1378/chest.06-3017. View

Walls J, Hong Y, Cox J, McCabe K, OBrien K, Allerton J . Pulmonary intravascular lymphomatosis: presentation with dyspnea and air trapping. Chest. 1999; 115(4):1207-10. DOI: 10.1378/chest.115.4.1207. View

10.

Pullamsetti S, Berghausen E, Dabral S, Tretyn A, Butrous E, Savai R . Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2012; 32(6):1354-65. DOI: 10.1161/ATVBAHA.112.248500. View

11.

Samuels N, Berkman N, Milgalter E, Bar-Ziv J, Amir G, Kramer M . Pulmonary hypertension secondary to neurofibromatosis: intimal fibrosis versus thromboembolism. Thorax. 1999; 54(9):858-9. PMC: 1745562. DOI: 10.1136/thx.54.9.858. View

12.

Madani M, Auger W, Pretorius V, Sakakibara N, Kerr K, Kim N . Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. Ann Thorac Surg. 2012; 94(1):97-103. DOI: 10.1016/j.athoracsur.2012.04.004. View

13.

Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Valeyre D . Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore). 1999; 78(5):321-37. DOI: 10.1097/00005792-199909000-00004. View

14.

Hoeper M, Bogaard H, Condliffe R, Frantz R, Khanna D, Kurzyna M . Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D42-50. DOI: 10.1016/j.jacc.2013.10.032. View

15.

Lee A, Levine M . Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003; 107(23 Suppl 1):I17-21. DOI: 10.1161/01.CIR.0000078466.72504.AC. View

16.

Hoeper M, Barst R, Bourge R, Feldman J, Frost A, Galie N . Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013; 127(10):1128-38. DOI: 10.1161/CIRCULATIONAHA.112.000765. View

17.

Kuga T, Kohda K, Hirayama Y, Matsumoto S, Nakazawa O, Ando M . Pulmonary veno-occlusive disease accompanied by microangiopathic hemolytic anemia 1 year after a second bone marrow transplantation for acute lymphoblastic leukemia. Int J Hematol. 1996; 64(2):143-50. DOI: 10.1016/0925-5710(96)00467-7. View

18.

Ghobadi G, Bartelds B, van der Veen S, Dickinson M, Brandenburg S, Berger R . Lung irradiation induces pulmonary vascular remodelling resembling pulmonary arterial hypertension. Thorax. 2011; 67(4):334-41. DOI: 10.1136/thoraxjnl-2011-200346. View

19.

Wang X, Ibrahim Y, Das D, Zungu-Edmondson M, Shults N, Suzuki Y . Carfilzomib reverses pulmonary arterial hypertension. Cardiovasc Res. 2016; 110(2):188-99. PMC: 4836627. DOI: 10.1093/cvr/cvw047. View

20.

Rai P, Cool C, King J, Stevens T, Burns N, Winn R . The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008; 178(6):558-64. PMC: 2542431. DOI: 10.1164/rccm.200709-1369PP. View